Literature DB >> 29737375

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.

Lawrence F Kuklinski1,2, Shaofeng Yan3, Zhongze Li4, Jan L Fisher5, Chao Cheng6, Randolph J Noelle7, Christina V Angeles8, Mary Jo Turk7, Marc S Ernstoff9.   

Abstract

Adaptive immune responses contribute to the pathogenesis of melanoma by facilitating immune evasion. V-domain Ig suppressor of T-cell activation (VISTA) is a potent negative regulator of T-cell function and is expressed at high levels on monocytes, granulocytes, and macrophages, and at lower densities on T-cell populations within the tumor microenvironment. In this study, 85 primary melanoma specimens were selected from pathology tissue archives and immunohistochemically stained for CD3, PD-1, PD-L1, and VISTA. Pearson's correlation coefficients identified associations in expression between VISTA and myeloid infiltrate (r = 0.28, p = 0.009) and the density of PD-1+ inflammatory cells (r = 0.31, p = 0.005). The presence of VISTA was associated with a significantly worse disease-specific survival in univariate analysis (hazard ratio = 3.57, p = 0.005) and multivariate analysis (hazard ratio = 3.02, p = 0.02). Our findings show that VISTA expression is an independent negative prognostic factor in primary cutaneous melanoma and suggests its potential as an adjuvant immunotherapeutic intervention in the future.

Entities:  

Keywords:  Checkpoint inhibitor; Melanoma; Survival; Tumor microenvironment; Tumor-infiltrating lymphocytes; VISTA

Mesh:

Substances:

Year:  2018        PMID: 29737375     DOI: 10.1007/s00262-018-2169-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Authors:  Alice Tzeng; C Marcela Diaz-Montero; Patricia A Rayman; Jin S Kim; Paul G Pavicic; James H Finke; Pedro C Barata; Marcelo Lamenza; Sarah Devonshire; Kim Schach; Hamid Emamekhoo; Marc S Ernstoff; Christopher J Hoimes; Brian I Rini; Jorge A Garcia; Timothy D Gilligan; Moshe C Ornstein; Petros Grivas
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 2.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

Review 3.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 4.  VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Authors:  Mohamed A ElTanbouly; Walburga Croteau; Randolph J Noelle; J Louise Lines
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

5.  Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful.

Authors:  Izabela Szulc-Kielbik; Michal Kielbik
Journal:  Exp Suppl       Date:  2022

6.  Expression of B7 family checkpoint proteins in cervical cancer.

Authors:  Liju Zong; Yu Gu; Yuncan Zhou; Yujia Kong; Shengwei Mo; Shuangni Yu; Yang Xiang; Jie Chen
Journal:  Mod Pathol       Date:  2021-11-30       Impact factor: 7.842

7.  Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Authors:  John de Groot; Marta Penas-Prado; Kristin Alfaro-Munoz; Kathy Hunter; Be Lian Pei; Barbara O'Brien; Shiao-Pei Weathers; Monica Loghin; Carlos Kamiya Matsouka; W K Alfred Yung; Jacob Mandel; Jimin Wu; Ying Yuan; Shouhao Zhou; Gregory N Fuller; Jason Huse; Ganesh Rao; Jeffrey S Weinberg; Sujit S Prabhu; Ian E McCutcheon; Frederick F Lang; Sherise D Ferguson; Raymond Sawaya; Rivka Colen; Shalini S Yadav; Jorge Blando; Luis Vence; James Allison; Padmanee Sharma; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

8.  Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Authors:  Jie Deng; Jiannan Li; Aurelien Sarde; J Louise Lines; Yu-Chi Lee; David C Qian; Dov A Pechenick; Richard Manivanh; Isabelle Le Mercier; Christopher H Lowrey; Frederick S Varn; Chao Cheng; David A Leib; Randolph J Noelle; Rodwell Mabaera
Journal:  Cancer Immunol Res       Date:  2019-05-14       Impact factor: 12.020

Review 9.  The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.

Authors:  Negar Hosseinkhani; Afshin Derakhshani; Mahdi Abdoli Shadbad; Antonella Argentiero; Vito Racanelli; Tohid Kazemi; Ahad Mokhtarzadeh; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 10.  VISTA: A Promising Target for Cancer Immunotherapy?

Authors:  Marco Tagliamento; Elisa Agostinetto; Roberto Borea; Mariana Brandão; Francesca Poggio; Alfredo Addeo; Matteo Lambertini
Journal:  Immunotargets Ther       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.